Living Cell Technologies Ltd says it has received ethical approval to start clinical trials for Parkinson's disease.
In a statement released today, the company says it received ethical approval from the New Zealand Ministry of Health's Health and Disability Ethics Committee to proceed with Phase I clinical trials of NTCELL® for Parkinson's disease.
Living Cell Technologies chief executive Dr Andrea Grant said: "We are extremely pleased to have received ethical approval in such an efficient timeframe.''
It intends to start its first in-human trials next year.
The company received regulatory authorisation from Medsafe to proceed with trials in October.
The company has a special quarantined piggery in Southland, where it keeps Auckland Island pigs, which are used in the company's diabetes research.